300
Participants
Start Date
April 6, 2023
Primary Completion Date
December 10, 2025
Study Completion Date
December 12, 2025
LT3001 Drug:high dose
Administered by intravenous infusion.
Placebo
Administered by intravenous infusion.
LT3001 Drug:low dose
Administered by intravenous infusion.
RECRUITING
Beijing Tiantan Hospital, Capital Medical University, Beijing
RECRUITING
Beijing Luhe Hospital Capital Medical University, Beijing
RECRUITING
Beijing Tsinghua Changgung Hospital, Beijing
RECRUITING
Beipiao Central Hospital, Chaoyang
RECRUITING
The First Bethune Hospital of Jilin University, Changchun
RECRUITING
Daqing Oilfield General Hospital, Daqing
RECRUITING
Shanghai Pudong Hospital, Shanghai
RECRUITING
The Second Affiliated Hospital of Soochow University, Suzhou
RECRUITING
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
RECRUITING
Huai'an Second People's Hospital, Huai'an
RECRUITING
Liaocheng People's Hospital, Liaocheng
RECRUITING
Zhejiang Hospital, Hangzhou
RECRUITING
Taizhou Municipal Hospital, Taizhou
RECRUITING
Taizhou First People's Hospital, Taizhou
RECRUITING
Pingxiang People's Hospital, Pingxiang
RECRUITING
Zhongnan Hospital of Wuhan University, Wuhan
RECRUITING
Luoyang Third People's Hospital, Luoyang
RECRUITING
The First Affiliated Hospital of Jinan University, Guangzhou
RECRUITING
Xi'an Gaoxin Hospital, Xi’an
RECRUITING
Yan'an University Xianyang Hospital, Xianyang
RECRUITING
Inner Mongolia Baogang Hospital, Baotou
RECRUITING
Harrison International Peace Hospital, Hengshui
RECRUITING
The First Affiliated Hospital of Baotou Medical College, Baotou
RECRUITING
The Third Hospital of Mianyang, Mianyang
RECRUITING
Linfen Central Hospital, Linfen
RECRUITING
Linfen People's Hospital, Linfen
RECRUITING
Nanshi Hospital of Nanyang, Nanyang
RECRUITING
Central People's Hospital of Zhanjiang, Zhanjiang
Shanghai Pharmaceuticals Holding Co., Ltd
INDUSTRY